Atopic Dermatitis

Treatment for atopic dermatitis isn’t always straightforward. In this article, a physician outlines treatment approaches.

In this article, we take a look at the development of new treatments for atopic dermatitis.

“Because atopic dermatitis is episodic, its incidence, prevalence, persistence, remission, flare and long-term control require careful definition,” researchers write.

New recommendations from the International Eczema Council aim to address a question that has gone largely unanswered: When should dermatologists and others prescribe systemic therapy to treat atopic dermatitis?

Atopic dermatitis patients have a phobia of topical corticosteroids that is so strong, it’s been described as a “phenomenon.”

A pilot study shows that Manuka honey may have some healing properties in atopic dermatitis.

Children under two years old with signs of atopic dermatitis have an increased risk of developing asthma and food allergies, researchers report in JAMA Pediatrics. And, young children with both early onset atopic dermatitis and a food allergy, have a “very high risk” of developing asthma or allergic rhinitis.

Patch testing for allergic contact dermatitis in the pediatric population is performed at a higher rate than previously reported, but still grossly underreported, according to a study of the Pediatric Contact Dermatitis Registry.

In this slideshow, we highlight four atopic dermatitis phenotypes in children as described in JAMA Pediatrics.

EADV study shows that this JAK inhibitor is a promising drug candidate in moderate-to-severe AD.

Ingredients used in topical products used to relieve atopic dermatitis in children might put those patients at higher risk for contact dermatitis.

NIH investigators find that Staphylococcus epidermidis is predominant in less severe cases, while Staphylococcus aureus is associated with patients who have more severe disease.

Nitric oxide-releasing cream that targets IL-17 moving toward clinical trials.

An experimental drug designed to control itching in people with moderate-to-severe AD shows promise in early trial.

A new study shows that mutations in the gene CARD11 are associated with severe atopic disease.

In early research, subcutaneous nemolizumab significantly reduced pruritus in moderate-to-severe atopic dermatitis adult patients.

Patients with severe atopic dermatitis who have lower serum vitamin D levels have a high sensitivity to house dust mites which can aggravate their condition, a new study shows.

Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.

The approval of dupilumab (Dupixent, Sanofi Regeneron) for moderate-to-severe atopic dermatitis adds a much-needed option that may alter the broader course of atopic disease, experts told Dermatology Times.

Atopic dermatitis (AD) is one of the most common skin conditions treated by dermatologists. As such, articles on atopic dermatitis tend to be some of the most popular Dermatology Times content. These are the top three AD articles.

When it comes to treating atopic dermatitis in non-white racial ethnic groups, there are variations in prevalence, genetic factors and clinical presentation.

Atopic dermatitis normalizes the skin micro biome. Anti-inflammatory medications for atopic dermatitis reduce colonization. Children with atopic dermatitis more prone to molluscum infection.

Emerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.

A recent study looked at the inpatient burden on patients with atopic dermatitis (AD) in the United States and found a significant financial burden due to the high hospitalization rates.

Drugs to treat atopic dermatitis are at the top of the FDA’s dermatology list. Biologics and PDE4 inhibitors show promise in the treatment of AD. Approval is still needed for the use of biologics to treat AD in pediatric patients.

The April Table of the Month discusses diagnostic and therapeutic tips for AD patients.

Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment

Promising new treatments recently approved or under development for atopic dermatitis include crisaborole, JAK inhibitors and dupilumab, an expert said.

Experts weigh in on what to know about the new addendum to the peanut allergy prevention guidelines.

The FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.